In Honor of Patti Spires 1967-2012
Patti Spires Hamilton was born at Ft. Meade, Maryland, on September 3, 1967, and passed away in Houston, TX on August 20, 2012. Her life was cut short by Alveolar Soft Part Sarcoma (ASPS), unfortunately undetected and unrecognized by the physicians who treated her for various other “ailments†during the past several years. Patti was […]
Support the annual fundraiser of Team ASPS riding for the 9th year the Pan-Massachusetts Challenge (PMC)
Dear Alveolar Soft Part Sarcoma Community This weekend, August 4-5th 2012, Team ASPS will ride for the 9th time the Pan-Massachusetts Challenge (PMC). The PMC is a bike-a-thon that crosses Massachusetts to raise money for cancer research and clinical trials at the Dana-Farber Cancer Institute in Boston. As in previous years, I am asking you […]
Update on the Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
If you consider to join the following clinical trial: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma ; study NCT01391962 Please note that patients can join only if: ·       Patients show evidence of disease progression ·       Patients must not have received prior treatment with any VEGF receptor tyrosine kinase inhibitor (e.g., cediranib, sunitinib, pazopanib, sorafenib); […]
Important Update on Cediranib development for Alveolar Soft Part Sarcoma (ASPS)
Dear ASPS community. Many of our patients who participated in Cediranib clinical trials reported on our FORUM positive ASPS response to the drug. The conclusion that Cediranib shows favorable activity in ASPS is detailed in a summary of a Phase 2 clinical trial by Dr. Kummar in the 2011 meeting of the American Society of […]
Happy New Year 2012!
Dear ASPS community, iCureASPS is wishing you all Happy 2012! We would like to thank our “Team ASPS†for the PMC bike ride. Our team has just completed another successful year of fundraiser, following their ride in August.  It is the 8th year that Team ASPS participates in the Pan-Massachusetts Challenge, a bike -a-thon that […]
Update on the Cediranib and Sunitinib Clinical Trials for Alveolar Soft Part Sarcoma Phase II in the USA
 Please note the two Phase II clinical trials available for ASPS patients in the US: 1.  Sunitinib or Cediranib for Alveolar Soft Part Sarcoma, study number NCT01391962 Contact: NCI Referral Office, Tel.  1-888-NCI-1937 Locations: United States, California Santa Monica Oncology Center Santa Monica, California, United States, 90403 United States, Maryland National Institutes of Health […]
New Clinical Trial for Alveolar Soft Part Sarcoma in the United Kingdom: CASPS – A Phase II Trial of Cediranib
Dear ASPS Community, We are very happy to report the opening of another clinical trial for ASPS patients in the United Kingdom. This new clinical trial is a phase II trial of Cediranib. Every trial brings with it the hope for cure! ASPS patients who are trying Cediranib are sharing their experience on iCureASPS Forum. […]
Support Research of ASPS: A Novel Mouse Tumor Model
In collaboration with iCureASPS, Dr. George Demetri, Dr. Massimo Loda, and Dr. Ewa Sicinska at the Dana Farber Cancer Institute in Boston have started a new initiative that aims to find an effective therapy for Alveolar Soft Part Sarcoma. This research will make use of a cell line that was established from a tumor taken […]
The Third Annual Knockin’ Down ASPS Event in the memory of Anthony Salisbury (AJ)
The third annual Knockin’ Down ASPS Event in the memory of Anthony Salisbury (AJ) took place in May. This year, over $12,000 was raised and donated directly to the laboratory of Dr. Glenn Dranoff at the Dana Farber Cancer Institute in Boston to support his efforts in finding a cure for Alveolar Soft Part Sarcoma. […]
NIH study finds Cediranib benefits patients with ASPS
An experimental drug, cediranib, may benefit alveolar soft part sarcoma (ASPS) patients, according a recent clinical trial. The trial, carried out by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health, showed that tumors shrank in more than 50 percent of ASPS patients who were treated with cediranib. These findings […]